INTRODUCTION
c-Jun is an oncogenic transcription factor that is present as a major component of the AP-1 (activator protein 1) transcription factor complexes. It has an NH 2 -terminal transactivation domain, a DNAbinding domain, and a leucine zipper domain in the COOH-terminal domain, through which it can dimerize (1, 2) . c-jun is an immediate early gene transcribed rapidly and transiently after stimulation of normal quiescent cells with different kinds of mitogens and tumor promoters. The expression of c-Jun is constitutively increased in many transformed cell lines (1, 2) and human cancers (3) , and overexpression of c-Jun alone can induce the transformation of immortalized rodent fibroblasts (4) and chicken embryo fibroblasts (5, 6) .
The regulation of c-Jun occurs both transcriptionally and translationally, and its activity can be regulated through phosphorylation and dimerization with different partners. c-Jun is phosphorylated by specific kinases called c-Jun NH 2 -terminal kinases (JNKs) and in some cell types also by mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK)-mediated mechanisms (7, 8) . JNKs (including 10 known isoforms) phosphorylate c-Jun within its NH 2 -terminal activation domain at Sers 63 and 73 (9) , which results in an increase in its transcriptional activity and stability (10 -12) . JNKs (mainly the ubiquitous isoforms 1 and 2) are known to be potently activated by cell exposure to UV radiation, pro-inflammatory cytokines, and environmental stress (13) (14) (15) but may also be activated during apoptosis, differentiation, morphogenesis, and oncogenesis (9) . JNK activation is triggered by dual phosphorylation on distinct Thr and Tyr residues by two specific MAPK kinases, MKK4 (SEK1) and MKK7 (9) . Finally, c-Jun can form homodimers and/or heterodimers, the latter preferred, with other Jun family members (JunB and JunD), Fos family members (c-Fos, FosB, Fra1, and Fra2), activating transcription factor proteins (ATF-2) and other proteins (e.g., Maf). The different complexes formed can then bind either to a 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive element (TRE; Refs. 16, 17) or to a cAMP-responsive element (CRE; Ref. 17) in the promoters of genes that regulate cell proliferation and differentiation.
The activation of c-Jun seems to be specifically required for progression through the G 1 phase of the cell cycle (18 -20) . Interestingly, in fibroblasts, c-Jun has recently been shown to control the cell cycle by acting as a direct negative regulator of p53 expression (21) . However, c-Jun may also act independently of p53 (22) . c-Jun has also been shown to be involved in the control of apoptosis (19, (23) (24) (25) . Not much is yet known about the molecular mechanisms involved, but there is some indication that the regulation of cell proliferation and apoptosis by c-Jun may be governed by at least two distinct pathways (19, 24) . Which pathway is selected may depend on the availability and formation of specific c-Jun dimerization complexes or on the other signaling pathways coincidentally activated. In addition, growing evidence in tissue culture and animal tumor models indicate that c-Jun is a central player in the control of cellular transformation. Indeed, the transforming activity of many known and putative oncogenes, such as activated receptor Tyr kinases, intracellular Tyr and Ser kinases, ras, S-adenosylmethionine decarboxylase (AdoMetDC), and nuclear oncoproteins c-Myc and SV40T, appear to be dependent on c-Jun activation (22, 26 -32) .
Recent studies have shown that ornithine decarboxylase (ODC), a key regulatory enzyme in the biosynthesis of polyamines (putrescine, spermidine, and spermine) is also a protein that, like c-Jun, is essential for mammalian cell proliferation (33) (34) (35) (36) (37) and may have role in cell transformation. Overexpression of ODC alone is sufficient to transform immortalized rodent cell lines (38, 39) , and, with the ras oncogene, it is able to transform primary cells (40) . ODC is also known to be highly activated in cells transformed by various carcinogens and oncogenes, such as v-src, neu, myc, and ras, as well as in a variety of clinical cancers (34 -37, 41-43) . Furthermore, inhibition of ODC activity with specific inhibitors or by dominant-negative mutants results in inhibition or reversion of transformation by v-src (39, 44) and ras (45, 46) . As to the possible mechanisms involved in ODCinduced transformation, we have previously detected constitutive activation of JNK and constitutively increased phosphorylation of the c-Jun transcription factor on Sers 63 and 73 in these transformants (41, 47) . These findings are similar to those obtained with ras, v-sis, v-src, raf-1, and polyomavirus middle-sized tumor antigen (13, 48 -54) , implying an important role specifically for c-Jun phosphorylation in the regulation of transformation.
In the present study, we examined the significance of c-Jun phosphorylation and activation in ODC-and Ha-ras-induced cell transfor-mation. We studied the effects of dominant-negative mutants of SEK1/MKK4 and JNK1, specific JNK inhibitors, two phosphodeficient mutants of c-Jun and a transactivation domain deletion mutant of c-Jun (TAM67) on the transformed phenotype of the cells. We also generated tetracycline-regulatable TAM67-expressing cell lines from the ODC-and ras-transformants, and show that the state of transformation and tumorigenicity of these cells can be effectively regulated by the expression of TAM67. These inducible cell lines provide good models to identify the molecular mechanisms relevant to cell transformation.
MATERIALS AND METHODS
Cell Culture. NIH3T3 cells stably transfected with the human ODC cDNA (Odc; Ref. 39) , the c-Ha-ras Val12 oncogene (pGEJ6.6; E4; Ref. 55 ) and an ODC-transformant derived from the Odc cell line-induced tumors in nude mice (Odc-n; Ref. 56) have been described previously. The cells were grown in DMEM containing antibiotics (penicillin, streptomycin, and gentamicin) and 5% fetal bovine serum (FBS; Bioclear) at 37°C in a 5% CO 2 atmosphere. The normal NIH 3T3 cells were grown in DMEM with antibiotics and 5% FBS or newborn calf serum (Life Technologies, Inc.).
The Odc, Odc-n, E4, and normal NIH 3T3 cells, stably transfected with a tetracycline-inducible expression system of c-Jun deletion mutant TAM67 (see below) were cultured as above or in MEM ␣ (␣-MEM) supplemented with gentamicin (50 g/ml) and 5% FBS, TET System Approved FBS (Invitrogen), or newborn calf serum.
Plasmids and Transfections. ). The transfections were performed without serum for 3 h. The cells were selected for resistance to puromycin (1.5 g/ml), which was added 2 days after transfection. Pools of transfectants and multiple individual clones (between 5 and 33) were isolated and selected for further analysis.
Generation of Cell Lines Carrying a Tetracycline-Inducible Expression System of the Transactivation Domain Deletion Mutant of c-Jun (pLRT-TAM67). The TAM67 mutant of c-Jun, lacking the transactivation domain, was released from pGEM3-T67 with EcoR1, and the fragment was cloned into pBluescript. Fragments in the sense orientation were released by XhoI/NotI digestion and cloned into XhoI/NotI-digested reverse tetracycline-regulated retroviral vector (62) . The pLRT-TAM67 plasmid (1 g) was transfected into the Odc, Odc-n, E4, and normal NIH 3T3 cells (on six-well plates) using LipofectAMINE Plus. Two days after transfection, selection was started with 5 g/ml blasticidin (Invitrogen) and continued for 1-2 weeks. The stable transfectants were maintained in 1 g/ml blasticidin. Several clones (transformed foci) were picked up by cylinder cloning for initial screening of the regulation of TAM67 expression, and the best ones were further subjected to single-cell cloning in 96-wells. The cloned cells were tested for their inducibility of TAM67 expression by adding 1 g/ml doxycycline (Sigma) 1 day after plating and by analyzing 2-3 days thereafter, the expression of TAM67 by immunoblotting and the morphological changes by microscopy.
Cell Lysates. Cells were harvested by scraping and centrifugation, and were washed 1-2 times with PBS. If not processed immediately, the cell pellets were kept frozen at Ϫ70°C until use. For whole cell extracts, the cells were lysed directly in a hot Laemmli sample buffer without 2-mercaptoethanol [62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, and 0.01% bromphenol blue]. The samples were sonicated on ice for 10 s, and the lysates were cleared by centrifugation. The protein concentration was determined using the BCA Protein Assay Reagent Kit (Pierce Chemical, Rockford, IL). Finally, 2-mercaptoethanol was added to a final concentration of 5% and the samples were boiled for 5 min.
Western Blotting. The whole cell lysates (20 -50 g) were resolved by SDS-PAGE (10% acrylamide) and were transferred onto 0.2-m nitrocellulose membrane (Bio-Rad trans-Blot transfer medium). The membranes were incubated in blocking buffer [25 mM Tris (pH 8.0), 125 mM NaCl, 0.1% Tween, 2% BSA, and 0.1% NaN 3 ] for 4 -16 h and then with specific antibodies for 2-4 h at room temperature or overnight at 4°C. The membranes were washed five times with the TBS-NP/T buffer [10 mM Tris (pH 8.0), 150 mM NaCl, 0.05% NP40, and 0.05% Tween] and were incubated 30 min at room temperature with horseradish peroxidase-conjugated swine antirabbit IgGs (DAKO), rabbit antimouse IgGs (DAKO) or goat antimouse IgG/IgM (Chemicon) in the TBS-NP/T buffer. Phospho-p38 MAPK antibody was bridged with biotinylated antirabbit IgG (Dako) and streptavidin-biotinylated horseradish peroxidase complex. The membranes were washed five or six times with the TBS-NP/T buffer, 15-30 min in high-salt buffer [10 mM Tris (pH 8.0), and 300 mM NaCl), and, finally, three times in TBS (10 mM Tris (pH 8.0) and 150 mM NaCl). The protein bands were visualized using enhanced chemiluminescence (ECL) detection system and exposition to FUJI Rx film. Equal loading was assessed by staining the membranes with Ponceau S solution (Sigma) and blotting with actin (see below). [APF]) were analyzed with rabbit polyclonal antibody to MKK4/SEK1/ JNKK1 (Sigma) and with mouse monoclonal antibody to the FLAG-tag, FLAG M2 (Sigma), respectively. Phosphorylated and total p38 MAPK were detected using polyclonal rabbit antibody to phospho-p38 (Thr180/Tyr182; Cell Signaling Technology, Inc.) and p38 (C-20; Santa Cruz Biotechnology), respectively. As a loading control, actin was probed with mouse monoclonal antibody to actin (Ab-1; Oncogene Research Products).
Analysis of Cell Growth. We studied the effect of TAM67 expression on the growth of the Odc, E4, and normal NIH 3T3 cells carrying the tetracyclineinducible expression system by recording the increase in cell number. The cells (5 ϫ 10 4 ) were plated in complete medium (␣-MEM or DMEM with 5% FBS or newborn calf serum) on 3-cm-diameter dishes in triplicates in the absence or presence of doxycycline (1 g/ml). During the next 4 days of culture, the cell numbers were determined every 24 h by Coulter counting.
Use of JNK Inhibitors in Cell Culture. L-Stereoisomer of JNK peptide inhibitor 1 (L-JNK Inhibitor 1) and L-stereoisomer of TAT control peptide (L-TAT; Alexis Biochemicals) were used at 0, 1, 5, 15, and 25 M concentrations. The peptides were added daily to the cultures, and the medium was changed every other day. JNK Inhibitor II (SP600125; Calbiochem), a novel, potent catalytic inhibitor (10 mM stock solution made in DMSO), was used at concentrations of 0, 0.1, 0.25, 0.5, 1, 2.5, 5, and 10 M and 0.1% DMSO as a control. The medium was changed every other day.
Soft Agar Growth. Cells (1 ϫ 10 4 ) in growth medium supplemented with 10% serum were mixed with agar (Noble agar; Difco) to yield a 0.35% agar mixture. The mixtures were then overlaid onto 0.7% bottom agar in 24 well plates. Both agar layers were made with or without doxycycline 1 g/ml. After polymerization, growth medium with or without doxycycline was added, and the medium was replenished twice a week. The colony formation was followed for 2-3 weeks.
Matrigel Invasion Assay. Twenty-four-well plates (Greiner) were coated with 300 l of Growth Factor Reduced Matrigel (Becton Dickinson Biosciences, Bedford, MA) diluted 1:3 in DMEM (supplemented or not with doxycycline, 1 g/ml). Matrigel was polymerized for 30 min at 37°C. Thereafter, 10 000 cells were plated on top of the Matrigel in 100 l of DMEM and allowed to adhere for 1 h at 37°C. Excess DMEM was removed, and 250 l Matrigel layered above the cells. Finally, 500 l of DMEM containing 10% FCS, without or with doxycycline (1 g/ml), was added on top of the Matrigel matrix. The growth medium was replenished every third day. The growth pattern of the cells in Matrigel was followed daily by microscopy and photography.
Tumorigenicity Assay. Six-week-old nude mice (HsdCpb:NMRI-nu) were obtained from Harlan Netherland, the Netherlands. Odc cells with inducible TAM67 expression system (1.5 ϫ 10 6 cells in 125 l of growth medium) were injected s.c. into both flanks of the mice. The mice received or not doxycycline (1 mg/ml) in the drinking solution (2% sucrose to mask the bitter taste of tetracycline), started 2 days before the injections and replaced at 2-day inter-vals. The mice were sacrificed before tumors reached 1 cm 3 in size or ulcerated. The tumors were weighed, and one-half of them were frozen in liquid nitrogen for molecular biological analyses and one-half were fixed with formalin and embedded in paraffin for histological analyses.
ODC Assay. ODC activity was assayed by measuring the release of 14 CO 2 from L-(1-14 CO 2 ) ornithine (55). Fig. 1A, c and d) . Similar results were obtained in cells derived from the ODC-overexpressor-induced tumors in nude mice (Odc-n; Fig. 1B, b) . DN JNK1 expression resulted in less prominent changes, causing partial reversion of the ODC-induced morphology (Fig. 1, A,e and B,c) . It is possible that the amount of DN JNK1 expression is not sufficient to attain complete inhibition of JNK1 and JNK2, of which the latter may be of more importance for transformation (63, 64) . We were, therefore, interested to study also the effects of the recently introduced cell-permeable inhibitors of JNKs: L-JNK Inhibitor 1, which binds to JNK1 and JNK2 with similar affinity and blocks their interaction with c-Jun (65), and JNK Inhibitor II, which potently blocks (K i , 0.19 M) the activity of all of the JNKs (66). Addition of increasing concentrations of L-JNK Inhibitor 1 (0. 1, 5, 15, and 25 M) to the Odc cell cultures resulted in slight flattening of the morphology of the cells at concentrations higher than 5 M, whereas the control peptide L-TAT did not have any appreciable effects at the same concentrations (Fig. 1C) . Similarly, JNK Inhibitor II caused a partial reversion of the transformed morphology of Odc cells at concentrations higher than 0.5 M, whereas bare 0.1% DMSO (the solvent) did not have any effect on the cell morphology (Fig. 1C) . For comparison, we also studied the effects of DN SEK1/MKK4 and DN JNK1 on the Ha-ras (Fig. 1D, b and  c) , whereas DN JNK1 had again a less prominent effect on the morphology (Fig. 1D,d ). (pMT 161) and a transactivation incompetent deletion mutant of c-Jun (TAM67) having most of the transactivation domain (amino acids 3-122) deleted (26) . A control transfection with wild-type c-Jun (pMT 108) retained the transformed morphology (Fig. 1, A, f and D,e) . The expression of the c-Jun mutants pMT 111 and pMT 161, instead, resulted in reversion of the ODC- (Fig. 1A, g and h) and ras- (Fig. 1D , f and g) induced morphology. Finally, in repeated experiments, the expression of the transcriptionally inactive c-Jun mutant TAM67 caused the most significant reversion of both the ODC-( Fig. 1 A, i and B,d) and the ras- (Fig. 1D,h ) transformed phenotype. The expression of DN SEK1/MKK4, DN JNK1, wild-type c-Jun (pMT 108), the phosphorylation defective c-Jun mutants (pMT 111 and pMT 161), and TAM67 in the above experiments was verified by Western blot analyses ( Fig. 2A, B, and D-F) ; it was verified as well that DN SEK1/MKK4 is not affecting p38 MAPK activation in Odc cells (Fig. 2C) . Of note is that the expression of TAM67 was associ- (Fig. 2, E and F) . This is likely caused by a transcriptional repression of the c-Jun gene, which is known to have a variant c-Jun response element in its promoter region (16) .
RESULTS

Dominant
The NH 2 -Terminal Phosphorylation Site Mutants and Transactivation Domain Deletion Mutant (TAM67) of c-Jun
The Transformed Phenotype of the ODC-and ras-Transformed Cells Is Reversibly Regulated by Tetracycline-Inducible Expression System of TAM67. Because we did not obtain stable cell lines expressing TAM67 (at high levels) because of a counterselection (growth inhibition; see below), and to obtain more definitive evidence that expression of TAM67 can reverse the ODC-and ras-induced morphology, we generated ODC-and ras-transformed cell lines in which TAM67 could be conditionally expressed. TAM67 was cloned into a reverse tetracycline-regulatable retroviral expression vector (62) and transfected into the ODC-and ras-transformed cells, and multiple (Ͼ25) stable cell clones were isolated. In all of the clones, the expression of TAM67 was tightly regulated by doxycycline addition (with no, or only tiny, leakage under the noninduced conditions) as evidenced by immunoblotting (Fig. 3) . As in transient transfection experiments, the induction of TAM67 expression resulted in downregulation of the endogenous c-Jun expression in both the ODC- (Fig.  3, A and B) and the ras-transformed (Fig. 3C) cells. To study specifically the transformation reversal and to avoid interfering with the serum growth-factor-induced early changes in gene expression, we chose to add doxycycline (induce TAM67) 1 day after passaging the cells. However, with regard to the data presented here, there was no difference if doxycycline was added immediately after the plating. The induction of TAM67 expression resulted in reversion of the transformed morphology to a more flattened appearance within 1-3 days of doxycycline treatment in both Odc-and E4-pLRT-TAM67 transformants (Fig. 4A, a and b and B, a and b) . Similar results were obtained with all of the clones analyzed. Titration with different concentrations of doxycycline (0.1-2.0 g/ml) revealed that the expression level of TAM67 correlated with the degree of reversal of the transformed morphology. After withdrawal of doxycycline, the cells returned to the transformed phenotype in 2-3 days, showing that the cellular transformation process can be reversibly regulated. The inducible expression of TAM67 made it possible to study specifically the effects of TAM67 on the ability of the cells to grow anchorage independently in soft agar and Matrigel. The induction of TAM67 in Odc cells markedly inhibited (Ͼ90%) cell growth in soft agar, and the colonies were reduced both in number and size when compared with the noninduced cells (Fig. 4A, c and d) . Similarly, the invasive growth potential of the ODC-and ras-transformed cells in Matrigel was highly reduced by TAM67 expression (Fig. 4A, e and f, and B, c  and d) . e and f, and B, c and d) . Doxycycline (dox) was added to the cells 2 days before they were transferred to soft agar and Matrigel. The morphology of the cells grown in the absence (Ϫdox) and presence (ϩdox) of doxycycline was documented by phase-contrast micrcoscopy and photography after 2 days, the number of soft agar colonies after 3 weeks, and the growth pattern in Matrigel after 3 days (Odc-pLRT TAM67) and 5 days (E4-pLRT TAM67) of culture. In addition to the morphological reversion, the expression of TAM67 resulted in the inhibition of growth of the ODC- (Fig. 5A) and ras-transformed cells. Interestingly, this was not the case with the normal NIH 3T3 cells, in which inducible expression of TAM67 had no significant effect on cell growth (Fig. 5B) . Finally, the activity of ODC was found to remain high in the TAM67-transfected Odc cells, both in the transiently transfected cells and in the cells carrying the inducible pLRT TAM67. After induction of TAM67 expression for 2 days, the ODC activity (which correlates with the amount of enzyme protein) was only minimally affected (24% decreased) relative to the noninduced control (Fig. 6 ). This small decrease in the ODC activity is likely secondary to the TAM67-induced growth inhibition. These data indicate that the reversal of transformation by TAM67 was not due to its blocking the ODC expression but to the inhibition of AP-1 mediated cellular events.
Expression of TAM67 Inhibits Tumor Formation in Nude Mice. Inoculation of Odc-pLRT TAM67 cells s.c. at both flanks of the mice having the control drinking solution (2% sucrose) resulted, in all cases, in rapidly growing tumors, fibrosarcomas with ulcerative tendency (Table 1, Fig. 7A ), whereas the mice receiving doxycycline for TAM67 expression in the drinking solution developed only very small or no tumors during the treatment period of 17 days (Table 1) .
Similarly to that, we have earlier reported for the ODC-transformed parental cells (56) , the uninduced Odc-pLRT TAM67 cells (in mice not having doxycycline) could invade locally to striated muscle and fat tissues (Fig. 7B) , whereas the small tumors, arisen from the Odc-pLRT TAM67 cells induced to express TAM67 by doxycycline supplementation, showed reduced invasive capacity (Fig. 7C) .
DISCUSSION
In our study, dominant-negative mutants of SEK1/MKK4 were found to reverse the morphology of the ODC-transformed cells, implicating that the JNK pathway is relevant to cellular transformation associated with overexpression of ODC. In support of this notion, transfection of DN JNK1 also resulted in a morphological change, but did not fully revert the transformed phenotype. It is possible that DN JNK1 is ineffective at blocking the functions of both JNK1 and JNK2. It is also conceivable that DN SEK1 not only blocks JNK function but also other kinases, resulting in the significant effect observed. The two different JNK inhibitors (L-JNK Inhibitor 1 and JNK Inhibitor II), inhibiting both JNK1 and JNK2 (65, 66) , resulted also in partial reversion of the transformed morphology; this supports the latter possibility of JNKs not being the only kinases involved in ODCinduced cell transformation. We also found a minor increase in p38 MAPK activation (phosphorylation) in Odc cells, but DN SEK had no effect on the phosphorylation of p38 MAPK, suggesting that DNSEK may still have other unknown sites of action. Similar findings were made in the ras-transformed E4 cells, i.e., that DN SEK1/MKK4 was more effective than DN JNK1 in reversing the transformed morphology. Previous studies in our laboratory have shown that, unlike the ODC-transformants, the ras-transformed E4 cells do not display constitutive activation of JNK, and that the MAPKs extracellular signal- (41, 47) . Altogether, these data suggest that a yet unidentified kinase(s) may additionally be involved in the maintenance of transformation of these cells. Considering this possibility, we note that, in mice, the deletion of SEK1/MKK4 causes a more severe phenotype than the combined knocking out of JNK1 and JNK2 (12) , which also suggests a broader spectrum of downstream targets for SEK1/MKK4.
In any case, both the ODC-and ras-transformed cells show a constitutive increase in the phosphorylation of c-Jun on the Ser residues 63 and 73 (41, 47) . In this study, we show that transfection of the ODC-and ras-transformants with the phosphorylation site mutants of c-Jun (c-Jun S63,73A and c-Jun S63,73A,T91,93A ) could reverse the transformed morphology. These data suggest an important role for c-Jun phosphorylation in the maintenance of transformation of the ODC-and ras-transformed cells. In concert with this data, Behrens et al. (51) have recently shown that the phosphorylation of c-Jun at Sers 63 and 73 is essential for the induction of ras transformation in genetically manipulated mice. Thus, these c-Jun mutants may provide viable tools for cancer therapeutic approaches.
However, TAM67, the transactivation domain deletion mutant of c-Jun, had the most potent transformation reversing effect of all of the c-Jun mutants tested, both in the case of ODC-and ras-induced transformation. This indicates that in addition to phosphorylation there are other ways by which c-Jun plays a role in the maintenance of these transformations. Noteworthy, a previous study has shown that c-Jun is also important for the induction of cell transformation by ras, as evidenced by the finding that cells lacking c-Jun are unresponsive to oncogenic forms of ras (28) . Of significance is that, although the signaling pathways through the different MAPK modules may vary depending on the cell type and growth conditions, all of these signalings appear to converge on c-Jun/AP-1 activity among others, making c-Jun/AP-1 an ideal candidate for therapeutic interventions.
Our results show that the expression of TAM67 was accompanied by down-regulation of endogenous c-Jun, presumably as a result of transcriptional repression through the variant AP-1 site in its promoter (16) . However, the TAM67 expression has also been reported not to interfere with endogenous c-Jun expression (67) . It is possible that the reduction of c-Jun in our study is due to achieving higher expression levels of TAM67. This may result in significant alteration of the composition of the AP-1 complexes.
Curiously, previous reports on the effects of TAM67 on rasinduced transformation have been conflicting. Whereas Brown et al. (26) and Rapp et al. (30) show that TAM67 affects the transformed morphology (rise of transformed cells on ras cotransfection), Janulis et al. (68) do not see these effects. These discrepancies may reflect differences in NIH 3T3 cell lines or may result, e.g., from different transfection systems and different TAM67 expression levels achieved. Indeed, our studies have revealed that the transfection protocol may greatly affect the results of transient transfection experiments, and that there may be a strong selection against the high TAM67 expressers, complicating the analyses. Clearly, the transient transfection assays should be interpreted with caution.
It is also important to note, that most of the previous studies have dealt with the effects of TAM67 on the induction of transformation and not on the established transformed cell lines studied here. Using a reverse tetracycline-inducible expression system, we could definitively establish that TAM67 can normalize the phenotype of the ODCand ras-transformed cells. TAM67 not only reversed the transformed morphology but also inhibited the proliferation of the ODC-and ras-transformed cells, whereas the growth of the normal cells was not significantly affected by TAM67. TAM67 also blocked the tumorigenic activity of the cells in nude mice. This raises an intriguing possibility that the inhibition of c-Jun/AP-1 by TAM67 could be effectively exploited in cancer gene therapy without having much adverse effect on the normal cells. The finding that TAM67 superceded the effectiveness of DN MKK4/SEK1, DN JNK, JNK inhibitors and phosphodeficient c-Jun mutants in transformation reversal is also a persuasive argument for TAM67 exploitation in future cancer therapeutic approaches. Moreover, our studies show that TAM67 can block the invasive capacity of the ODC-and ras-transformed cells. Finally, as TAM67 expression and the transformation state of the cells can be conditionally regulated, the ODC-pLRT TAM67 and raspLRT TAM67 cell lines together with their parental transformed and normal cell counterparts, offer powerful tools to explore and characterize the genes crucial for cellular transformation. As an indication of this, our initial screening of about 9500 genes in these cell lines by cDNA microarray analyses have revealed that there is only a surprisingly small number of potential transformation relevant genes. Fig. 7 . Odc-pLRT TAM67 cells induce ulcerated and invasive tumors in nude mice in a TAM67 expression-sensitive manner. The experiment was performed as described in the legend of Table 1 . A, the tumors formed were fixed in formalin, embedded in paraffin, cut in 5-m sections and stained with H&E. Odc-pLRT TAM67 cell-induced tumor with ulceration in a mouse not having doxycycline to drink (Ϫdox). There is a lack of the normal epidermis in the ulcer (arrow). B, invasion of the tumor cells into striated muscle (arrow) and fat tissue in the untreated (Ϫdox) mouse. C, reduced invasion of the tumor cells into striated muscle (bottom right) in a mouse treated with doxycycline (ϩdox). A, ϫ100; B and C, ϫ200.
